

RNS Number: 6150A

AIM

20 July 2007

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ('AIM RULES')

COMPANY NAME:

ReSearch Pharmaceutical Services Inc.

(formerly Cross Shore Acquisition Corporation)

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES): Registered Office : Corporation Trust Centre, 1209 Range Street, Wilmington, DE 19801, USA

Principal place of business following readmission: 520 Virginia Drive, Fort Washington, PA, 19034 U.S.

COUNTRY OF INCORPORATION:

USA

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:
www.rpsweb.com

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING STRATEGY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

Predominantly operating in the US and headquartered in Pennsylvania, RPS is a provider of integrated clinical development outsourcing solutions to the bio-pharmaceutical industry. RPS services are provided in connection with the design, initiation and management of clinical trials programs, a critical element in obtaining regulatory approval for bio-pharmaceutical products. RPS introduced the Pharmaceutical Resource Organization ('PRO') model to address the changing demands of the drug development industry, which continues to grow rapidly but is facing increasing pressures to control costs and improve effectiveness. The PRO model combines the capabilities of a specialty staffing organization with the expertise of a clinical research organization ('CRO'), enabling RPS to offer a model that is gaining traction in the market. The success of its PRO model, which combines its newly introduced Clinical Master Service Provider ('CMSP') program with more traditional CRO and specialty staffing related services, has resulted in RPS' net revenues growing from \$12.6 million in 2000 to approximately \$84.4 million for 2006.

RPS provides a broad range of clinical development services to its clients to support the design, initiation and management of clients' clinical trials programs, each of which are critical aspects in the regulatory approval process for bio-pharmaceutical products. The Directors and the Proposed Directors believe that a key differentiator is RPS' ability to deliver these services in a manner that is fully integrated with the client's infrastructure. The PRO model contrasts with that of a traditional CRO, which focuses on performing individual clinical trials on behalf of its client by mirroring the pharmaceutical company's infrastructure with limited interface with the client until the final deliverable is achieved. The Directors and the Proposed Directors believe that RPS' PRO model more effectively utilizes the existing resources, processes and systems of its clients, while enhancing real-time communication and coordination with clients, avoiding duplicative infrastructure costs. In addition, the Directors and the Proposed Directors believe that RPS' recruiting and staffing capabilities combined with the clinical infrastructure represent a competitive advantage in attracting and retaining the high quality personnel required to successfully execute the PRO model and compete with CROs.

RPS attempts to develop strong strategic relationships with its clients at the senior levels of an organization and then designs customized outsourcing solutions that 'carve-out' key functional areas of the client's clinical development infrastructure to be outsourced to RPS. The PRO solution emphasizes close integration with the client so that the client can selectively outsource those areas in which the greatest savings can be realized while permitting the

client to maintain control of the key medical and regulatory decision-making processes. The result is what is often called a 'functional' or 'cross-functional' outsourcing model, which embeds RPS within the client's infrastructure, creating a strategic and interdependent relationship.

RPS delivers its services through three service models:

Clinical Master Services Provider: This is a long-term strategic relationship developed with senior management within a client's clinical, financial and procurement departments that generally involves a partial or full 'carve-out' of functional areas of the client's development efforts.

Project Solutions: The deployment of the traditional CRO approach in which RPS has full project-management responsibility for a discrete project of finite length. Under this approach RPS is responsible for an entire trial or specific aspects of a trial for a particular compound.

Other Solutions: Similar to staff augmentation services provided by specialized staffing firms. RPS provides personnel on a consulting basis to its clients to supplement their own staff.

RPS is being admitted by way of reverse takeover by Cross Shore Acquisition Corporation (AIM: CSE).

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

Up to 42,003,422 common shares of par value \$0.0001 each ('Common Shares'); and

Up to 2,986,667 warrants to subscribe for Common Shares ('Warrants')

Shares and Warrants will trade as Restricted Reg S stock.

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

No capital to be raised on admission. Anticipated market capitalisation - TBC

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

Approximately 36%

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:
None

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Daniel Max Perlman 'Dan' (Chief Executive Officer and Chairman of the Board)

Edward Van-Ching Yang 'Ed' (Executive Director)

Harris Koffer (President, Chief Operating Officer and Executive Director)

Dennis Michael Smith (Executive Director)

Daniel Raynor 'Dan' (Non-Executive Director)

Steven E. Stonefield (Non-Executive and Independent Director)

James Robert Macdonald (Non-Executive Director)

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name

by which each is known or including any other name by which each is known):

Based on the Share register as at 2 July 2007, the Company is aware of the following shareholders holding 3% or more of the Shares of the Company:

Name	Number of Shares Held		Approximate Percentage of Issued Shares	
	As at the date of this document	Immediately following Re-admission	As at the date of this document	Immediately following Re-admission (1)
CSA I, LLC	1,805,387	644,781	7.7%	1.5%
CSA II, LLC	1,041,583	322,390	4.5%	0.8%
CSA III, LLC	1,330,710	475,254	5.7%	1.1%
Daniel Max Perlman 'Dan'	-	2,551,613	-	6.1%
Argentum Capital Partners	-	5,766,605	-	13.7%
First Analysis Corporation	-	3,454,128	-	8.2%
Cost Nominees Limited	1,548,333	1,548,333	6.6%	3.7%
Highline Capital	975,900	975,900	4.2%	2.3%
LBPB Nominees Limited	1,166,667	1,166,667	5.0%	2.5%
Lehman Brothers International	1,070,334	1,070,334	4.6%	2.8%
Morstan Nominees Limited	2,373,334	2,373,334	10.2%	5.7%
NCB Trust Limited	1,570,124	1,570,124	6.7%	3.7%
Och-Ziff Capital Management	3,232,334	3,232,334	13.9%	9.0%
Scopia Partners	809,876	809,876	3.5%	1.9%
Third Point Partners	1,000,000	1,000,000	4.3%	2.4%

(1) These percentages are determined after giving effect to the repurchase of 3.0 million Founding Shares, the issuance of the Exchange Shares to the Selling Securityholders as partial consideration for the Acquisition and the issuance of the Sunrise Shares in connection with the Sunrise Option Tender and assume 100 per cent. of the Existing Warrants are exchanged for Shares pursuant to the tender offer no exercise of Repurchase Rights and subsequent cancellation of Shares by the Company.

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: none

- (i) ANTICIPATED ACCOUNTING REFERENCE DATE
- (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED
- (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

(i) 31 December

(ii) 31 December 2006

(iii) Next three results to be published on:

a) Interim results for 6 months to 30 June 2007 by 30 September 2007

b) Annual results for 12 months to 31 December 2007 by 30 June 2008

c) Interim results for 6 months to 30 June 2008 by 30 September 2008

EXPECTED ADMISSION DATE:
7 August 2007

NAME AND ADDRESS OF NOMINATED ADVISER:

Arbutnot Securities Limited
Arbutnot House
20 Ropemaker Street
London,
EC2Y 9AR

NAME AND ADDRESS OF BROKER:

Arbuthnot Securities Limited
Arbuthnot House
20 Ropemaker Street
London,
EC2Y 9AR

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

Arbuthnot Securities Limited
Arbuthnot House
20 Ropemaker Street
London,
EC2Y 9AR

DATE OF NOTIFICATION:

20 July 2007

NEW/ UPDATE:

New

This information is provided by RNS
The company news service from the London Stock Exchange

END

PAAOKKKKBNBKDPOB

SUBJECT: GEN
COMPANY: CSE USU1549T1098 ZZZZZZZZZZZZ